Tel Aviv, Israel, and Parsippany, New Jersey, U.S., November 11, 2026
Teva Pharmaceutical Industries Ltd. has unveiled its next phase of pharmaceutical research and development (R&D) strategy, outlining an ambitious target of generating $6–7 billion in innovative medicines revenue by 2030. During its first-ever R&D Day, the global biopharmaceutical company presented updates on its expanding clinical pipeline, innovative drug discovery capabilities and plans to introduce potentially one new innovative medicine annually over the next five years. The announcement highlights the company’s continued transformation under its Pivot to Growth strategy, launched in 2023, which focuses on strengthening innovative medicines, expanding biosimilars and improving long-term financial performance. Teva reported that its innovative medicines revenue has more than doubled since the strategy began, supported by established brands and a growing portfolio of investigational therapies. The company also highlighted a late-stage pipeline with more than $10 billion in combined potential peak sales, subject to successful clinical development and regulatory approvals. The latest strategy places significant emphasis on immunology, neuroscience, oncology and respiratory diseases, positioning Teva to strengthen its presence in the global pharmaceutical market.
Teva Expands Innovative Drug Pipeline Across Therapeutic Areas
Teva is advancing multiple innovative drug candidates targeting significant unmet medical needs across several therapeutic areas. One of the important programmes involves its anti-IL-15 antibody, TEV-‘408, which is being developed for autoimmune conditions, including celiac disease and vitiligo. The company reported that its Phase 2a study in celiac disease achieved its primary endpoint, with a Phase 2b study expected to begin in the second half of 2027. In vitiligo, TEV-‘408 is progressing toward a Phase 2/3 clinical study following encouraging Phase 1b results. Teva is also evaluating its potential in additional indications, including alopecia. Another important programme is ATTENUKINE™, an investigational anti-PD-1/IL-2 therapeutic candidate currently undergoing Phase 1 clinical development for advanced cancer. The company reported encouraging early efficacy signals and a favorable safety profile to date. This programme reflects Teva’s growing interest in developing innovative immuno-oncology medicines that combine targeted immune regulation with potential anticancer activity. The company is also strengthening its next-generation antibody discovery capabilities. Its early-stage pipeline includes precision antibody programmes targeting TSLP/IL-13 and TL1A/IL-23, with potential applications in respiratory and inflammatory diseases, including asthma and inflammatory bowel disease. These programmes are designed to address complex disease pathways through more targeted biological approaches.
Clinical Development Progress Supports Future Drug Launches
Teva highlighted its differentiated R&D model, which combines internal discovery, external scientific partnerships and data-driven clinical development decisions to accelerate promising drug candidates. The company aims to shorten development timelines while maintaining scientific quality and regulatory standards. Several programmes have already demonstrated progress through accelerated clinical development pathways. WELTRUZA™ (olanzapine extended-release injectable suspension) advanced directly from Phase 1 into Phase 3 development. The company also highlighted ecopipam, which received FDA Priority Review, and its anti-IL-15 programme in vitiligo, which is advancing through a combined Phase 2/3 development strategy. Teva’s broader late-stage pipeline includes duvakitug, an anti-TL1A antibody being developed for ulcerative colitis and Crohn’s disease, and its dual-action rescue inhaler programme for asthma. These candidates represent important potential growth drivers as the company expands beyond its established innovative medicines portfolio. According to Richard Francis, President and Chief Executive Officer of Teva, the company has built a stronger research and development platform by combining biotechnology-style agility with the commercial capabilities and global infrastructure of an established pharmaceutical organization. The strategy is designed to translate scientific discoveries into new medicines while maintaining a disciplined approach to investment and clinical development.
Advertisement
Teva Sets $6–7 Billion Revenue Ambition for 2030
Alongside its clinical pipeline updates, Teva presented its financial ambitions for the next stage of business growth. The company is targeting $6–7 billion in innovative medicines revenue by 2030, supported by new product launches, expanding commercial operations and continued investment in pharmaceutical research. Its financial outlook also includes an innovative medicines gross margin target exceeding 75%, mid-single-digit total revenue growth between 2026 and 2030, and free cash flow exceeding $3.5 billion by 2030. Teva is additionally targeting a net debt-to-adjusted EBITDA ratio of 2.0 times by the end of 2027. The company reported that innovative medicines now account for more than 20% of its total revenue, while its gross profit margin reached approximately 55% as of the third quarter of 2026. Teva also generated more than $6 billion in free cash flow between 2023 and 2025. The latest R&D strategy demonstrates Teva’s commitment to expanding its innovative pharmaceutical portfolio while maintaining its established generics and biosimilars businesses. Its ambition to potentially launch one innovative medicine annually through 2030 highlights the growing importance of research-driven growth in the global pharmaceutical industry. Successful clinical outcomes, regulatory approvals and commercial execution will determine whether Teva achieves its long-term growth targets.
Source: Teva Pharmaceuticals press release
